Effects of soy beans isoflavone in the vagina and the uterum in the post menopausal womens

Effects of Glycine max (L.) Merr in the vaginal epitelium and the endometrium in post menopausal women

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

REBEC

Registry ID

RBR-88vgp6

Enrollment

Unknown

Registered

2012-01-04

Start date

2011-01-01

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal atrophy Menopause Treatment Women

Interventions

Group 1: 30 women in use of intravaginal gel with Glycine max (L.) Merr isoflavone, 1 gr/day/90 dias. Group 2: 30 women in use of intravaginal gel placebo, 1gr/day/90 days

drug

A05.360.319.779

Eligibility

Sex/Gender

Female

Age

45 Years to 68 Years

Inclusion criteria

Inclusion criteria: Women with age 45-68 years old Vaginal atrophy simptons Menopause >12 months With out hot flushes No contraindications for hormonal terapy

Exclusion criteria

Exclusion criteria: Hot flushes symptons Breast neoplasy and endomtrium With Hormonal teraphy

Design outcomes

Primary

Measure	Time frame
The vaginal atrophy symptons with isoflavone gel will be less than placebo gel. The maturation index of vaginal citology will going to evaluated and by transvaginal ultrasonography the endometrium will going to evaluated	—

Secondary

Measure	Time frame
There should be an increase in the number of the vaginal cells in use of isoflavone gel	—

Countries

Brazil

Contacts

Public Contactsilvia saito

faculdade de ciencias medicas da santa casa de sao paulo

sisaito@hotmail.com11 36677833

Outcome results

None listed

Source: REBEC (via WHO ICTRP)